Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

作者：Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, G. Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Lei Feng, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiao‐Jing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang · 发表于：The Lancet Oncology · 年份：2021 · DOI：10.1016/s1470-2045(21)00302-8 · 被引用次数：462 · 研究领域：Head and Neck Cancer Studies、Cancer Immunotherapy and Biomarkers、Head and Neck Surgical Oncology